+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Geriatric Assessment in Older Patients with Acute Myeloid Leukemia

Geriatric Assessment in Older Patients with Acute Myeloid Leukemia

Cancers 10(7)

The incidence of acute myeloid leukemia (AML) increases with age, but the outcomes for older adults with AML are poor due to underlying tumor biology, poor tolerance to aggressive treatment, and the physiologic changes of aging. Because of the underlying heterogeneity in health status, treatment decisions are difficult in this population. A geriatric assessment (GA) refers to the use of various validated tools to assess domains that are important in older adults including physical function, cognition, comorbidities, polypharmacy, social support, and nutritional status. In older patients with cancer, a GA can guide treatment decision-making, predict treatment toxicity, and guide supportive care interventions. Compared to solids tumors, there is a relative lack of studies evaluating the use of a GA in older patients with AML. In this review, we will discuss the principles, common domains, feasibility, and benefits of GA, with a focus on older patients with AML that includes practical applications for clinical management.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 065175356

Download citation: RISBibTeXText

PMID: 29986389

DOI: 10.3390/cancers10070225

Related references

Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leukemia Research 37(9): 998-1003, 2013

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 98(2): 208-216, 2013

Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. Cancer Treatment Reviews 75: 52-61, 2019

The prognosis value of comprehensive geriatric assessment in elder patients with acute myeloid leukemia in a single center. Zhonghua Xue Ye Xue Za Zhi 40(3): 200-203, 2019

The usage of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a multicenter, prospective study. Zhonghua Xue Ye Xue Za Zhi 40(1): 35-39, 2019

Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. Clinical Lymphoma, Myeloma and Leukemia 18(5): E211-E218, 2018

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. Cancers 10(7), 2018

Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission. Annals of Hematology 2019, 2019

Geriatric assessment in acute myeloid leukemia: current and future landscape. Blood Advances 2(18): 2418, 2018

Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. Journal of Geriatric Oncology 2019, 2019

Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clinical Lymphoma, Myeloma and Leukemia 11 Suppl 1: S54-S59, 2012

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 113(9): 2504-2511, 2008

Can we incorporate geriatric assessment in the management of acute lymphoblastic leukemia in older adults?. Journal of Geriatric Oncology 9(4): 296-301, 2018

Efficacy of high dose and intermediate dose cytosine arabinoside in patients with secondary acute myeloid leukemia refractory acute myeloid leukemia and relapsing acute myeloid leukemia. Blut 51(3): 211, 1985

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22): 4422-4429, 2011